Day: January 5, 2023

AUSTIN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading Infrastructure and Environmental services provider, announced that L. Joe Boyer, Chief Executive Officer, and Jonathan Parnell, Chief Strategy Officer will participate in the CJS Securities 23rd Annual New Ideas for the New Year Conference, which is being held virtually, on Wednesday, January 11, 2023. Atlas’s presentation at the event will begin at 3:05 PM Eastern time. The live presentation can be accessed here or through the Company’s Investor Relations website at ir.oneatlas.com. About Atlas Technical ConsultantsHeadquartered in Austin, Texas, Atlas is a leading provider of Infrastructure and Environmental Solutions. We partner with our clients to improve performance and extend the lifecycle...

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT (10:30 a.m. ET). A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days. About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have...

ANDOVER, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, announced today that Seth Bagshaw, Senior Vice President, Chief Financial Officer and Treasurer, will participate in a virtual fireside chat at the 25th Annual Needham Growth Conference on Thursday, January 12, 2023, at 2:15 p.m. (EST). A live webcast of the session will be available in the Investor Relations section of the company’s website at https://investor.mks.com/ and a replay of the event will be available for a limited time thereafter. About MKS Instruments MKS Instruments enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications....

SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced today results from a project in collaboration with global biotechnology leader CSL (ASX: CSL), confirming that SAB’s DiversitAb™ platform can generate functional fully-human anti-idiotype polyclonal antibodies that can effectively target and neutralize autoantibodies associated with autoimmune diseases. Autoantibodies are immune system proteins that can mistakenly target the body’s own organs and tissues. Autoantibodies can target almost every part of the body and are found in a wide range of autoimmune diseases, such as lupus, autoimmune...

– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 – – Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). “Initial Phase 1 clinical data demonstrate that ALG-055009 is favorably differentiated...

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility solutions, announced the initiation of an Energy Performance Contracting program for Dooly County School System in Georgia. Creating $3.7 million in projected energy and operating cost savings over a twenty-year period, ABM’s custom solution addresses capital and operational upgrades through ABM’s unique ability to deliver both energy-saving infrastructure solutions and ongoing services such as custodial and maintenance. “Our technical and financial solutions help communities make sure the benefits of their investment are tangible for today’s students,” said Mark Hawkinson, President of ABM Technical Solutions. “We not only improve infrastructure through projects like this for our clients, but we also protect and preserve those investments...

EDGEWOOD, N.Y., Jan. 05, 2023 (GLOBE NEWSWIRE) — CPI Aerostructures, Inc. (CPI Aero® or the Company) (NYSE American: CVU) announced today that an undisclosed aerospace OEM has awarded CPI Aero a $1.8 million contract for complex welded fluid tank assemblies for an unspecified application. Deliveries will begin in 2023 and end in 2024. “This follow-on order demonstrates our customer’s satisfaction with CPI Aero’s performance and continued commitment to excellence. This fluid tank assembly involves complex fusion and resistance welding, and leverages strategic investments CPI Aero has made in welded product capabilities since 2019. These investments were key to the successful transition of this program from development to production, resulting in improved quality and increased throughput,” commented Dorith Hakim, president and chief...

DiaCarta Starts to Receive Samples for Oncuria® Bladder Cancer Test at its CLIA Lab PLEASANTON, Calif. and LOS ANGELES, Jan. 05, 2023 (GLOBE NEWSWIRE) — DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (“Nonagen”), a cancer diagnostics company, today announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test (“LDT”). DiaCarta also announced that it has begun receiving patient urine samples for testing in its CLIA certified lab in Pleasanton, California. Oncuria is a multiplex protein-based urine test aiming to provide early and accurate detection, therapy choice, and disease monitoring of bladder cancer. Oncuria detects concentrations of 10 proteins associated with bladder cancer in urine samples....